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Abstract
Encapsulating cytostatics into lipid vesicles, i.e. liposomes, improves tumour drug 
accumulation and reduce adverse effects. Liposomal doxorubicin (DXR) has been used in the 
treatment of a variety of cancers and may also be suitable for combining with other treatment 
modalities. By modulating liposomal membranes, liposomes can be made ultrasound (US) 
sensitive releasing encapsulated drug in tumour tissue upon external US stimulation and may 
thereby improve therapeutic outcome. Moreover, as DXR is a potent radiosensitizer, 
liposomal DXR could enhance the effect of radiotherapy (RT) primarily in tumour tissue. 
This thesis evaluates multimodal cancer therapy combining liposomal DXR with US and RT 
in tumour-bearing mice. Also, the feasibility of using in vivo fluorescence optical imaging 
(OI) to study liposome tumour uptake was evaluated. Enhanced therapeutic effect of 
liposomal DXR was observed when combined with US applied to tumour. Liposomal DXR 
also improved therapeutic outcome of RT under radioresistant hypoxic conditions. The role of 
OI in quantitative assessment of liposome tumour uptake remains unresolved.  
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1. Introduction 
1.1 Cancer 
Each year more than 12 million people are diagnosed with and 7.6 millions die from cancers 
worldwide. The cancers most commonly diagnosed are lung, breast and colorectal cancers 
while the most common causes of cancer deaths worldwide are cancers of lung, stomach and 
liver [1]. In Norway one in three will develop cancer by the age of 75 [2]. 
Cancer cells derive from normal cells. Normal cells however, divide at a controlled rate and 
participate in constructing a variety of tissues and functions. By contrast, cancer cells have an 
uncontrolled cell division and are less differentiated than healthy cells, lacking the ability to 
perform their intended functions [3]. 
Transformation from healthy to malignant tissue is a step-wise process where tissues of 
intermediate appearances can be identified. A modest deviation from healthy tissues are 
hyperplastic growths in which cells deviate only minimal in appearance but the numbers of 
cells are increased. An equally minimal deviation from healthy tissues is termed metaplasia,
i.e. when one type of cell is displaced by an other cell type having normal appearance but not 
usually present at the location. A more abnormal growth is termed dysplasia. In this case the 
excessive numbers of cells also have abnormal appearances. All these growths are benign. 
However, if the transformation continues a malignant primary tumour may be the end 
product. Malignant tumours may grow invasively into neighbouring tissues and cancer cells 
may also spread by the bloodstream and lymphatic system forming metastases in sites far 
away from the primary tumour. Metastases are responsible for 90 % of deaths from cancer. 
Although there are exceptions, the transformation from healthy cells to cancer cells may 
progress over years or even decades. Most cancers are diagnosed at older age, indicating that 
tumour progression may be a long process. For a review see [3]. 
85 % of cancer cases involve solid tumours [4] characterized by a disorganized architecture 
with malfunctioning cells. Immature blood supply frequently fails to deliver oxygen and 
nutrients to rapidly dividing cells resulting in a tumour microenvironment characterized by 
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hypoxia and reduced pH. Reduced vascular functions represent a major obstacle for 
successful cancer treatment as therapeutic agents are not sufficiently delivered to less 
vascularised regions. Hypoxia also reduces the effect of treatment, i.e. radiotherapy (RT) and 
cytostatics. For a review see [5]. 
Causes of cancers may be numerous, i.e. genetics, physical and chemical carcinogens, 
lifestyles and infections [6]. However, as different cancers occur at very different frequencies 
between populations, numerous factors of both environmental and hereditary nature may 
participate in producing cancer [3]. 
Upon cancer diagnosis the most common treatment approach for solid tumours involve 
surgical removal of tumour tissue and if necessary followed by RT and/or chemotherapy. 
However, an increasing number of other therapeutic agents are also being used, e.g. 
immunotherapies and anti-angiogenic therapies [6].  
1.2 Prostate cancer 
The prostate gland is located at the neck of the bladder in males and contributes to the 
production of the seminal plasma. The glandular tissue is surrounded by a connective tissue 
capsule. Of the 26000 new cancer cases in Norway in 2008, 4200 were prostate cancer (PCa) 
making PCa the most common cancer among males in Norway [2]. PCa is classified clinically 
by the tumour size, lymph node involvement, and presence of metastasis according to the 
TNM-system (Table 1) [7] and histologically by the Gleason score [8]. Also, levels of 
prostate specific antigen (PSA) in the blood are used for diagnosis, deciding treatment 
strategy and treatment monitoring [9-11]. 
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Tumour, node, metastasis (TNM) classification of PCa
Primary tumour (T) Regional lymph nodes (N) Distant
metastasis (M) 
T0: No evidence of primary tumour N0: No positive regional 
lymph node(s) metastasis 
M0: No distant 
metastasis 
T1: Clinically inapparent tumour neither 
palpable nor visible by imaging 
N1: Metastasis in regional 
lymph node(s) 
M1: Distant 
metastasis 
T2: Tumour confined within prostate 
T3: Tumour expands through the prostate 
capsule
T4: The tumour has invaded other nearby 
structures
Table 1. TNM classification of PCa. 
Treatment of PCa depends on the stage of the disease, whether the intention of treatment is 
curative or palliative as well as the patient’s view on potential side effects. For curative 
treatment; surgery, external RT or brachytherapy, i.e. implantation of a radioactive source in 
the prostate, are being used. Further, external RT and brachytherapy or external RT and 
hormonal therapy, i.e. androgen deprivation therapy (ADT), may also be given in 
combinations [12]. Palliative treatments are commonly performed by administering 
combinations of ADT, surgery, RT and cytostatics. Taxanes is currently the cytostatics of 
choice [9,12]. Also, other innovative treatments such as high intensity focused ultrasound 
(HIFU) are being performed in localized and low or intermediate-risk PCa [13,14]. 
Radical prostatectomy is the only surgical technique performed with curative intentions. 
Other surgical procedures, like removal of metastases, are performed for palliative purposes. 
However, surgery involving the prostate may lead to significant side effects [12]. 
Radiation is administered both for curative and palliative intentions. It is either given by 
external RT or by brachiotherapy [12]. 
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PCa arise as an “androgen-dependent” form, i.e. it is dependent of androgens to grow and 
consequently ADT may inhibit tumour growth for periods up to several years. However, ADT 
never cure PCa and after a remissive period the disease may enter an “androgen-independent” 
form where tumour growth occurs without the presence of androgens. Androgen-independent 
PCa does not respond to ADT [15]. 
PCa often develops slowly and may, especially in older patients, never progress into clinical 
PCa before the patients die of other reasons. Curative PCa treatment may involve serious side 
effects limiting quality of life. Therefore, several aspects have to be considered when deciding 
upon treatment. In patients with low risk of disease progression, watchful waiting may be 
employed, a strategy where treatment is actively postponed and the patient is routinely 
examined for progression of the disease [16]. Even though a variety of treatments are 
available, the numbers of deaths due to PCa are increasing [2] indicating that new treatment 
strategies are needed. 
1.3 Liposomes 
Liposomes are simple colloidal vesicles with an aqueous interior enclosed by a membrane 
usually composed of phospholipid (PL) molecules. PLs, the major components of biological 
membranes, are amphiphilic compounds with a polar head group and lipophilic acyl chains. 
PLs can be classified according to type of polar head group, fatty acid chain length and degree 
of saturation [17]. Figure 1 illustrates the structures of dioleoylphosphatidylethanolamine 
(DOPE), distearoylphosphatidylethanolamine (DSPE) and distearoylphosphatidylcholine 
(DSPC), which are PLs used in this thesis. 
                                            DOPE: R1=R2= C18:1, R3= -CH2CH2NH3
                                            DSPE: R1=R2= C18:0, R3= -CH2CH2NH3
                                            DSPC: R1=R2= C18:0, R3= -CH2CH2N(CH3)3
Figure 1. General structure of PLs and the structures of DOPE, DSPE and DSPC. 
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When bilayer forming PLs are dispersed in aqueous media they will spontaneously align 
themselves in a manner to reduce interactions between the polar media and the hydrophobic 
fatty acid chains. Consequently, bilayered structures, i.e. liposomes, may be formed. 
Liposomes may consist of one or more bilayers (lamellae) and of sizes ranging from tens of 
nanometres to tens of micrometers in diameter. For a review see [17]. Liposomes are broadly 
classified into small unilamellar vesicles (SUV; single bilayer, size 10 - 100 nm), large 
unilamellar vesicles (LUV; single bilayer, size 100 - 1000 nm), multilamellar vesicles (MLV, 
several bilayers, size 100 nm - 20 um and multivesicular vesicles (MVV, size 100 nm - 20 
um) [18].  
Since liposomes were first described 45 years ago [19] they have gained interests for a variety 
of applications including drug delivery [20]. Liposomes used for drug delivery are usually 
about 100 nm in size and are made up of a single bilayer. As liposomes comprise an aqueous 
core sealed of by a PL membrane both hydrophilic and lipophilic drugs can be accommodated 
in their respective compartments [18]. Today there are about 15 liposomal drugs approved for 
clinical applications or undergoing clinical evaluation [20]. Figure 2 presents a schematic 
illustration of drug encapsulated in a liposome. 
Figure 2. Liposomal encapsulated drug. Epitarget©
1.4 Liposomes in cancer treatment 
Conventional cytostatics used in cancer treatment are small molecular weight molecules [4]. 
Such molecules distribute non-specifically to both healthy and tumour tissue resulting in 
therapy limiting toxicities. To increase the therapeutic-to-toxicity ratio cytostatics can be 
encapsulated into small liposomes (~100 nm), which accumulate in tumours due to the 
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enhanced permeability and retention effect [21]. Here, leaky tumour vessels allow 
macromolecules to extravasate into tumour tissue, whilst reduced lymphatic tumour drainage 
results in particle accumulation. 
First generation liposomes used for drug delivery suffered from fast clearance by cells of the 
monocyte phagocyte system (MPS). By coating liposomes with polyethylene glycol (PEG), 
i.e. pegylated liposomes, adhesion of plasma proteins and opsonins to liposomes are 
decreased. Consequently, immune system recognition is reduced, decreasing MPS uptake and 
prolongs circulation time [22]. Today, most liposomes used for drug delivery are pegylated. 
1.5 Liposomal doxorubicin 
The anthracycline anti-neoplastic drug doxorubicine (DXR) is active against a variety of 
tumours [23]. DXR is also very suitable for liposomal encapsulation due to the remote 
loading technique resulting in high drug-to-lipid levels [24]. Also, encapsulated DXR forms 
an insoluble gel contributing to stability [24]. Due to these unique properties liposomal DXR 
is on of the most studied liposomal drugs. 
During cancer therapy involving conventional DXR, adverse effects on cardiac functions are 
commonly encountered. In contrast, by encapsulating DXR into pegylated liposomes, i.e. 
pegylated liposomal DXR (PL-DXR), accumulation in the heart is reduced, enabling the 
administration of greater drug doses [25,26]. The PL-DXR formulation Caelyx® has been 
used in the treatment of several solid tumours [22,24], including PCa [27-30] for which only a 
modest benefit was reported. However, these studies were performed with patients having 
progressed cancer, i.e. metastatic androgen-independent PCa, and the results may therefore 
not be clinically relevant for less advanced PCa. 
1.6 Triggered drug release 
Upon liposome tumour accumulation encapsulated drug has to become bioavailable prior to 
exerting cytotoxic actions [31]. Therapeutic effect of stable, long circulating liposomes may 
be hampered by decreased drug release in tumour tissue [24,32]. Finding methods to 
destabilize liposomes within tumour tissue are therefore nontrivial and could lead to 
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substantial increase in drug bioavailability with concurrent improved therapeutic outcome 
[24].
Several approaches have been proposed to induce drug release from liposomes including 
hyperthermia [33], enzymatic [34] and pH [35] mediated strategies. However, a growing line 
of evidence suggests that ultrasound (US) may enhance liposomal drug release improving 
therapeutic efficacy [36-38]. 
1.7 Ultrasound mediated drug delivery 
US is defined as the transmission of pressure waves of frequencies above 20 kHz, which is 
the upper limit of human hearing [37]. US used in medical imaging employ frequencies 
between one and 20 MHz [39] delivered at low intensities (Watt/cm2) [40]. In contrary, 
therapeutic US is generally delivered at medium and high intensities, and broadly classified 
according to frequency employed; low frequency US (LFUS), i.e. 20 - 100 kHz, and high 
frequency US (HFUS), i.e. 1 - 3 MHz [40]. Therapeutic US are used for a verity of purposes 
[40], including non-invasive HIFU treatment of PCa [14,41] and uterine fibroids [42]. Here, 
focused US of frequencies typically between 1 - 3 MHz are used to ablate tissues. 
US can also be used for drug delivery purposes presumably due to acoustic cavitation, i.e. the 
oscillating movement of gas bubbles in a tissue exposed to US. A medium exposed to US will 
experience alternating intervals of high and low pressures. Under such conditions gas bubbles 
will expand at low pressures and contract at high pressures resulting in an oscillating 
movements of gas bubbles. When the oscillation is stable over several cycles it is termed 
stable cavitation. If, however, the US increases in magnitude the oscillating movements may 
result in collapse of gas bubbles, a process called inertial cavitation. During inertial cavitation 
neighbouring cell membranes or drug carrying vesicles can become transiently permeated, i.e. 
sonoporated [43,44]. Although not fully understood, cavitating gas bubbles in the vicinity of 
drug carriers are believed to be responsible for drug release. For reviews see [37,45,46]. 
In addition to inducing drug release from liposomes US may increase distribution of drugs in 
tumours, as well as increase cellular drug uptake [37]. US may also generate heat increasing 
extravasation of circulating drug carriers [47]. Consequently, US beneficial effects go beyond 
inducing drug release. 
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1.8 Sonosensitive liposomes 
To render carrier molecules US-responsive the presence of air have traditionally been viewed 
necessary, e.g. liposomes containing air [48,49] and liposomes linked to microbubbles [50,51] 
have been developed. These structures are however, in micron scale and too large to 
extravasate prior to US treatment, limiting their use in cancer therapy. However, by changing 
membrane lipid composition, small liposomes (~100 nm) have been made US-responsive [52-
54]. Such vesicles have the potential for both proper tumour accumulation and efficient drug 
release. Figure 3 illustrates a schematic representation of the treatment concept. 
Figure 3. US mediated drug delivery from liposomes. Epitarget©
1.9 Liposomal doxorubicin in chemoradiotherapy 
During tumour growth abnormal tumour vasculature frequently fails to supply sufficient 
levels of oxygen to tumour tissue, resulting in various degrees of hypoxia [55,56]. Tumour 
hypoxia is a well documented obstacle in achieving adequate response to RT as well as to 
other treatments including chemotherapy. Further, hypoxia is also known to promote 
malignant progression including metastatic development [57-59] and several strategies have 
been suggested to produce effective RT under hypoxic conditions [60,61].
Conventional cytostatics may also combine with RT, i.e. chemoradiotherapy (CRT), to 
enhance the effect or RT. Cytostatics may be used concurrent with RT, but also prior to, 
neoadjuvant, or after, adjuvant. Two such treatment modalities may interact positively and 
produce either additive or synergistic effects [62]. In strict sense a true “radiosensitizer” 
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should have no inherent cytotoxic activity [62]. However, the term is commonly used less 
strict and through this thesis it is used for any compound that enhances the effect of RT. 
DXR is an efficient radiosensitizer [63-65] and by enclosing DXR into liposomes, drug 
distribution to tumours may be enhanced. Consequently, radiation sensitization may primarily 
be located to tumour tissue, reducing toxicities in neighbouring healthy tissues where less 
sensitizing drug would have accumulated [66,67]. Both PL-DXR [66,68] and non-pegylated 
liposomal DXR [69] have reportedly increased the effect of RT in animal models. Also, 
promising results have been obtained from smaller clinical studies [67,70]. 
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2. Aim of thesis 
This overall aims of this thesis were to investigating the potential therapeutic benefits of 
combining PL-DXR with other treatment modalities, i.e. US and RT, in preclinical models. 
Also, assessing the feasibility of using small animal fluorescence imaging, i.e. optical imaging 
(OI), during the development of liposomal formulations. The specific aims were to: 
• Determine if the presence of DSPE in the liposomal membrane may render 
liposomes both US-responsive and stable in the blood stream. 
• Assess if LFUS treatment can enhance the therapeutic outcome of DSPE-based 
liposomal DXR in mice bearing prostate cancer xenografts. 
• Investigate how different levels of DOPE in the liposomal membrane influence US-
sensitivity and stability in vivo.
• Examine if liposome labelling with the carbocyanine lipophilic tracer 1,1’-
dioctadectyl-3,3,3’,3’,-tetramethylindotricarbocyanine,4-chlorobenzenesulfonat salt (DiD) is a 
suitable labelling technique for in vivo applications. 
• Investigate if OI is a suitable imaging modality for studying biodistribution of 
fluorochrome labelled liposomes. 
• Assess the impact of PL-DXR on vascular functions in prostate tumour xenografts. 
• Examine if therapeutic effect of RT on hypoxic prostate xenografts may be enhanced 
by the co-administration of PL-DXR. 
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3. Materials and methods 
3.1 Animals 
Male atymic nude Balb/c mice were provided by the Department of Comparative Medicine, 
Radium Hospital, Oslo University Hospital, Oslo, Norway. The mice were housed in 
transparent boxes with bedding material, fed ad libitum and kept under specific pathogen-free 
conditions. The temperature and relative humidity were kept constant at 20 – 21 °C and 60 %, 
respectively. At the end of the experiments all animals were euthanized by cervical 
dislocation. All procedures were performed according to protocols approved by the National 
Animal Research Authority and carried out in compliance with the European Convention for 
the Protection of Vertebrates Used for Scientific Purposes. The animals were 4 - 6 weeks old 
at time of tumour implantation (Paper I, III, IV and section 5.1 and 5.2).
3.2 Tumour models 
CWR22 human androgen dependent prostate adenocarcinoma, initially obtained from patients 
during surgery [71], were serially transplanted between mice. By blunt dissection through a 
skin incision above the caudal spine, a tumour fragment (~2x2x2 mm) was subcutaneously 
implanted on the flank (Paper I and section 5.2) or on the upper leg (Paper IV and section 
5.1). The skin incision was sealed with topical skin adhesive. 
22Rv1 human prostate adenocarcinoma (American Type Culture Collection, Manassas, VA, 
USA) is a cell line derived from CWR22 [72]. Cells were cultured in RPMI 1640 containing 
L-glutamine and NaHCO3 (Sigma Aldrich, Oslo, Norway) supplemented with 10 % foetal 
bovine serum (Fisher Scientific, Oslo, Norway) and 100 units/ml + 0,1 mg/ml of Penicillin-
Streptomycin (Sigma Aldrich, Oslo, Norway) at 37 °C in air containing 5 % CO2. 106 tumour 
cells suspended in 50 μl supplement free growth medium was mixed 1:1 (v:v) with Matrigel®
(VWR Oslo, Norway) and injected subcutaneously on the leg of mice and left to grow for 2-3 
weeks until start of experiment (Paper III and section 5.1). 
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LEW2AX human liposarcoma, initially obtained from patients during surgery, were serially 
implanted in nude mice to generate subcutaneous xenografts (section 5.2). LEW2AX grows 
slower and more homogenous than the prostate models also used in this thesis. 
3.3 Anaesthetics 
For anaesthesia of mice, a mixture of 2.4 mg/ml tiletamine and 2.4 mg/ml zolazepam 
(Zoletil® vet, Virbac Laboratories, Carros, France), 3.8 mg/ml xylazine (Narcoxyl® vet, 
Roche, Basel, Switzerland) and 0.1 mg/ml butorphanol (Torbugesic®, Fort Dodge 
Laboratories, Fort Dodge, IA, USA) in sterile water was prepared and used. The dosage used 
was 0.05-0.1 ml/animal (Paper I, II, III and IV, section 5.1 and 5.2). 
3.4 Ultrasound 
In vivo US treatment (Paper I) was performed with a 40 kHz ultrasonic processor (Model VC 
754, Sonic and Materials Inc., Newtown, CT, US) with a 19 mm diameter probe partially 
submerged into a cylinder containing deionized water, degassed by boiling, and cooled in ice 
bath. The bottom of the cylinder was sealed with a latex membrane in firm contact with the 
skin covering the tumour of an anesthetized mouse located on an adjustable plate. A thin layer 
of US gel was placed between the skin and the latex membrane. The US probe was run for a 
duration of four minutes and with a two cm distance between the probe and the skin. 
In vivo US treatment (section 5.1) was performed with a focused 1.13 MHz confocal, i.e. two 
US transducers, setup developed at Dr. Cyril Lafon’s lab, INSERM, Lyon, France. In brief, a 
tumour-bearing mouse was located on an adjustable plate with the xenograft facing upwards 
in firm contact with a latex membrane supported by a grid, creating a degassed water 
reservoir. The two US transducers and an imaging US probe were anchored to a metal rack 
(Figure 4). The metal rack was submerged into the water reservoir and positioned so that the 
cavitation zone was between the skin surface and the centre of the tumour. The correct 
positioning of the cavitation zone was assured by the US imaging probe. US treatment was 
performed for one minute with the animals under anaesthesia. 
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Figure 4. The two US transducers were anchored to a metal rack having identical focal spots. 
The presence of an imaging US probe ensured proper positioning of the cavitation zone 
within the tumour xenograft. INSERM©
In vivo US treatment (section 5.2) was performed using a 250 kHz focused US transducer 
(Model H115, Sonic Concepts, Bothell, WA, USA) connected to a cone shaped water 
chamber (C103 polycarbonate coupling cone for Model H115, Sonic Concepts, Bothell, WA, 
USA). A mouse bearing a tumour xenograft on the flank was located on an adjustable plate 
with an opening for the xenograft to be exposed downwards. The exposed xenograft was 
partially submerged into the water chamber containing degassed water that had been cooled in 
ice bath. US treatment was performed for five minutes with the mouse under anaesthesia. 
3.5 In vivo fluorescence optical imaging 
In vivo fluorescence imaging was performed with an IVIS® Imaging System 100 Series with 
XFO-6 Fluorescence Option (Xenogen corp., Alameda, CA, USA) (Paper III and section 5.1). 
All images were acquired using a Cy5.5 excitation filter (wavelength 615 - 665 nm), Cy5.5 
background excitation filter (wavelength 580 - 610 nm) and Cy5.5 emission filter (wavelength 
695 - 770 nm). Imaging data analysis was performed with Living Image® 2.5 software 
(Xenogen corp., Alameda, CA, USA) by subtracting the fluorescence background for each 
acquisition. Quantitative data for tumour fluorescence was obtained by manually drawing a 
region of interest (ROI) around the tumours visible margins. Average counts (sum of all 
counts inside ROI/no of pixels in ROI) were used during data interpretation. Prior to imaging, 
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the mice were sedated with 0.05 ml of anaesthetic agent sc. Figure 5 presents a representative 
image of tumour-bearing mice administered DiD labelled liposomes. 
Figure 5: In vivo fluorescence imaging. Mice bearing 22Rv1 prostate tumour xenografts 
administered DiD-labelled liposomes. Fluorescence intensity is highest in tumour and liver 
regions. The mouse to the left is untreated. 
3.6 Radiotherapy 
Mice bearing xenogtafts were irradiated using 60Co source (Mobaltron 80, TEM instruments, 
Crawley, UK) with a dose rate of 0.8 Gy/min. Each mouse were located in a custom designed 
vicryl tube containing an opening for the tumour-bearing leg to be stretched out and fixated 
horizontally. During the procedure only the tumour-bearing leg extended into the radiation 
field. The procedure was performed under sedation induced by 0.05 ml of anaesthetic agent 
(Paper IV). 
3.7 Dynamic contrast enhanced magnetic resonance imaging 
MRI acquisitions were performed as previously described [73], using a 1.5 T GE Signa LS 
scanner (GE Medical Systems, Milwaukee, WI), and a dedicated MRI mouse coil [74]. Prior 
to MRI, a heparinized 24 G catheter attached to a cannula containing 0.01 ml/g body weight 
of the contrast agent Dotarem® (Laboratoire Guerbet, Paris, France) diluted in heparinized 
saline to 0.06 M, was inserted into the animals’ tail vein. The animals were placed in an 
adapted cradle and put into the mouse coil, before being placed in the scanner. During image 
acquisition, the animal’s temperature was maintained at 38 °C. Dynamic contrast enhanced 
magnetic resonance imaging (DCE MRI) were performed by acquiring 5 baseline T1-
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weighted image acquisitions followed by contrast injection over a period of three seconds. 
Contrast kinetics was investigated by 20 minutes of post-contrast imaging. Figure 6 presents 
T1-weighted images of a mouse bearing prostate xenografts. 
Figure 6. Cross section T1-weighted images of a mouse bearing two CWR22 prostate 
xenografts. Varying xenograft signal intensities can be observed: A; pre, B; 1 minute post and 
C; 20 minutes post iv administration of Dotarem®.
Image analysis was performed using in-house developed software in IDL (Interactive Data 
Language v 6.2, Research Systems Inc., Boulder, CO). For the central slice of each tumour, a 
ROI was manually drawn in the T1-weighted images, excluding surrounding skin and 
connective tissue. The time-dependent relative signal intensity, RSI(t), was calculated for each 
image voxel according to Equation 1. 
Equation 1:
SI(0)
 SI(0)- SI(t)
RSI(t) =
where SI(0) refers to the pre-contrast signal intensity and SI(t) the post-contrast signal 
intensity in the voxel at time t.
Pharmacokinetic modelling was performed using the Brix model [75]. The Brix model is a 
two-compartment pharmacokinetic model where the contrast agent is assumed to distribute 
between two individually well-mixed compartments; the blood plasma and the extracellular 
extravascular space (EES) in the tumour. The iv injected contrast agent is transported into the
tumour by perfusion, where it diffuses between the plasma and the EES, before being 
eliminated at a constant rate. Using the RSI(t) for each voxel in the tumor ROI, the Brix model
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(Equation 2) was fitted using the Levenberg-Marquardt least-squares minimization method 
(MPFIT; http://purl.com/net/mpfit) [76].
Equation 2: )
telk-e-
tep-ke(
kk
Ak
RSI(t)
epel
ep
where the parameter kep is the rate constant between plasma and EES, kel the clearance rate of
contrast agent from plasma, and A an amplitude parameter related to the size of the EES [77]
(Paper IV). Figure 7 portrays tumour uptake and elimination of Dotarem® in a CWR22
prostate xenograft. 
Figure 7. Mean RSI(t) from all voxels in a tumour ROI. The Brix model was fitted using the 
Levenberg-Marquardt least-squares minimization method. The plot illustrates a characteristic 
rapid tumour contrast uptake followed by gradual elimination from the tumour. 
3.8 Immunohistochemistry 
Hypoxia was determined by injecting 80 mg/kg pimonidazole hydrochloride (1-[(2-hydroxy-
3-piperidinyl)propyl]-2-nitroimidazole hydrochloride (Natural Pharmacia International, Inc.,
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Burlington, MA, USA), dissolved in saline, ip to tumour-bearing mice. One hour later 
euthanasia was performed by cervical dislocation and tumours were excised and preserved in 
phosphate-buffered 4 % formalin until tissue sectioning. Tumour hypoxia was detected using 
a peroxidase-based immunostaining method. In brief, tissue sections were stained using the 
Dako EnVision™+ System-HRP (DAB) (K4011) and Dakoautostainer. Deparaffinization and 
unmasking of epitopes were performed using PT-Link (DAKO) and EnVision™ Flex target 
retrieval solution, high pH. To block endogenous peroxidase, sections were treated with 0.03 
% hydrogen peroxide for 5 min. The preparations were incubated 30 minutes with polyclonal 
rabbit antibodies to pimonidazole-protein adducts (1:10000 dilution). The sections were then 
incubated with peroxidase labeled polymer conjugated to goat anti-rabbit secondary 
antibodies for 30 minutes. Tissue was stained for 10 minutes with 3’3-diaminobenzidine 
tetrachloride (DAB) and counterstained with haematoxylin, dehydrated and mounted, and 
mounted in Diatex (Paper IV). 
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4. Summary of publications 
Paper I 
Ultrasound enhanced antitumour activity of liposomal doxorubicin in mice 
Eirik Hagtvet, Tove J. Evjen, Dag Rune Olsen, Sigrid L. Fossheim, Esben A. Nilssen 
Journal of Drug Targeting, published 
DSPE-based liposomes were evaluated as a potential US-sensitive delivery vehicle for DXR. 
In vitro characterization demonstrated 20 % DXR release from liposomes after four minutes 
of LFUS exposure in addition to high stability in serum assay. The biodistribution profile of 
the formulation was investigated by administering a drug dose of 3.5 mg DXR/kg to mice 
bearing prostate tumour xenografts. Approx 10 % of administered drug dose was accounted 
for in the blood 24 hours post injection indicating acceptable circulation time. High levels of 
DXR were also detected in liver and spleen. Tumour drug uptake reached plateau levels 
around 24 hours post injection. 
Therapeutic effect was assessed by administering a drug dose of 3.5 mg DXR/kg to tumour-
bearing mice. LFUS was delivered to the tumour 24 hours post injection by a 40 kHz US 
setup for a duration of four minutes. Therapeutic response was evaluated by tumour size 
measurements for 22 days. Neither DSPE-based liposomal DXR nor LFUS produced any 
growth inhibiting effect. However, DSPE-based liposomal DXR in combination with LFUS 
produced a significant reduction in tumour growth compared to the group administered only 
DSPE-based liposomal DXR. 
Levels of dissolved gases, viscosity, plasma proteins etc. might affect drug release and clearly 
varied between in vitro and in vivo experiments in current study. It can therefore not be 
concluded that similar drug release levels were achieved both in vitro and in vivo. It renders 
that the observed tumour growth inhibition might also result from other effects induced by 
LFUS, such as enhanced cellular drug uptake and improved liposomal extravasation. 
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Nevertheless, the study demonstrates that LFUS may enhance the effect of DSPE-based 
liposomal DXR. 
Paper II 
Sonosensitive dioleoylphosphatidylethanolamine-containing liposomes with prolonged 
blood circulation time of doxorubicin
Tove J. Evjen, Eirik Hagtvet, Esben A. Nilssen, Martin Brandl, Sigrid L. Fossheim 
European Journal of Pharmaceutical Sciences, published 
DOPE-based liposomes were evaluated as potential US-sensitive delivery vehicles for DXR. 
Liposome formulations containing DOPE levels between 12 and 62 mol % were evaluated for 
in vitro US-sensitivity by using a 40 kHz US setup. US sensitivity increased with increasing 
DOPE content, i.e. the formulations comprising 12 and 62 mol % DOPE experienced a drug 
release of 11 % and 91 % respectively. For liposomes to sufficiently accumulate in tumour 
tissues a prolonged circulation time is considered necessary. Hence, the kinetic profiles of the 
formulations were investigated by administering a drug dose of 7 mg DXR/kg to mice. The 
formulations with the highest DOPE content, i.e. 52 and 62 mol % experienced a fast DXR 
clearance. In contrary, the formulations containing 25 and 32 mol % had a kinetic profile 
similar to Caelyx®, with approximately 20 % of the administered DXR dose accounted for in 
the bloodstream 24 hours after iv injection. DXR content in liver and spleen indicated that the 
faster blood clearance for DOPE-rich formulations was not the result of enhanced uptake by 
MPS but due to increased leakage of DXR from the liposome carriers. It should not be 
excluded however, that the different blood clearance of liposomes comprising different DOPE 
levels could be due to accumulation in tissues not investigated in the study, such as the skin or 
paws.
The reduction in liposomal DOPE content to 25 and 32 mol % did not significantly reduce US 
mediated DXR release in vitro, indicating that DOPE is a potent modulator of sonosensitivity. 
The study suggested that by modulating the liposomal membrane it is possible to combine 
high US-sensitivity with prolonged circulation time. 
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Paper III 
Assessment of liposome biodistribution by non-invasive optical imaging: A feasibility 
study in tumour-bearing mice
Eirik Hagtvet, Tove J. Evjen, Esben A. Nilssen, Dag Rune Olsen 
Journal of Nanoscience and Nanotechnology, submitted 
The study evaluated the feasibility of using OI to study liposome accumulation in tumours. 
PL-DXR (Caelyx®) was labelled with DiD, a lipophilic carbocyanine tracer commonly used 
to label cells and liposomes for in vivo applications. No change in liposome size or serum 
stability was observed after the labelling procedure. Also, all administered dye appeared to be 
liposome associated in vitro.
The labelled liposomes were administered to mice bearing prostate xenografts at a dose of 14 
mg DXR/kg iv. Subsequently, the in vivo distribution of the labelled liposomes was followed 
over time by OI acquisitions. The results revealed a gradual increase in tumour fluorescence, 
indicating accumulation of the liposomes reaching plateau levels at 48 hours post injection. 
Parallel groups of animals were imaged at 24 or 48 hours post injection followed by sacrifice 
and tissue quantification of DXR and DiD. Blood sample analysis revealed that DiD levels 
where lower than DXR levels at both 24 and 48 hours indicating a faster elimination of DiD 
than DXR from the blood. The different elimination rates strongly suggest that DiD 
dissociated from liposomes in vivo. A similar scenario was seen in tumour tissue were more 
DXR than DiD were accounted for. This finding could presumably be explained by the 
dissociation of DiD from liposomes within the blood circulation resulting in more DXR than 
DiD being transported to tumour. Moreover, if DiD dissociated from liposomes in the 
circulation it will presumably, due to its highly lipophilic nature, associate with lipoproteins 
and other blood components leading to liver uptake. This may explain the significantly higher 
DiD levels in liver compared to DXR at both 24 and 48 hours post injection. 
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The fact that DiD seemingly dissociated from liposomes during circulation questions the 
suitability of DiD as a quantitative marker for liposomes in vivo. The results also indicate that 
in vivo cell application of carbocyanine dyes may have limitations. 
In vivo measured fluorescence intensity correlated only weakly (R2=0.59) with actual tumour 
DiD levels indicating that substantial scattering and absorption of in vivo fluorescent signal 
rendered it difficult to obtain reliable quantitative correlations between the biodistribution 
profile of the labelled liposomes. 
Paper IV 
Liposomal doxorubicin improves radiotherapy response in hypoxic prostate cancer 
xenografts
Eirik Hagtvet, Kathrine Røe, Dag Rune Olsen
Radiation Oncology, submitted 
Tumor hypoxia prevents effective RT and several strategies have been suggested to increase 
the effect of RT under hypoxic conditions. As DXR is known to enhance the effect of RT the 
current study examines the therapeutic benefit of combining PL-DXR (Caelyx®) with RT on 
radioresistant hypoxic tumours. PL-DXR was administered to mice bearing prostate 
carcinoma xenografts in combination with RT, both under normoxia and hypoxia, the latter 
being induced by clamping the tumour-bearing leg prior to and during RT. Treatment was 
assessed by tumour volume measurements for 29 days. RT alone had a profound antitumor 
effect, and literary stopped tumour growth. However, the effect of RT was significantly 
reduced when performed under hypoxic conditions. Moreover, concomitant administration of 
PL-DXR at a dose of 3.5 mg/kg significantly improved the therapeutic outcome of RT in 
hypoxic tumours. 
To assess therapy mediated changes to tumour vascular functions DCE MRI with subsequent 
pharmacokinetic analysis, was performed pre-treatment (baseline) and 8 days later. Further, 
parallel groups of animals were used to assess hypoxic fractions by immunohistochemistry of 
excised tumour tissue. The pharmacokinetic DCE MRI parameters and hypoxic fractions 
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suggested PL-DXR to induce tumour growth-inhibitory effects without interfering with 
tumour vascular functions. This feature is highly beneficial with respect to concomitant RT 
since well vascularised tumours may be more oxygenated and more likely respond better to 
RT. Moreover, PL-DXR appeared to reduce some of the vascular damaging effects produced 
by RT under hypoxic conditions. 
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5. Brief presentation of non-published studies involving 
DOPE-based liposomes
Incorporating DOPE in the liposomal membrane may be a promising approach for rendering 
liposomes US-responsive. This section presents in brief two animal studies performed with 
DOPE-based liposomes. The studies are not included in any publications. 
5.1 In vivo liposome sonosensitivity evaluated by optical imaging
When fluorochromes are encapsulated in high concentrations within liposomes the 
fluorescence signal emitted will be reduced, i.e. quenched [78,79]. Upon release of 
encapsulated substances fluorescence signal will increase and US mediated drug release may 
therefore be visualized by OI. 
To evaluate liposome sonosensitivity in vivo, liposomes encapsulating the near infrared (NIR) 
fluorochrome, Al(III) Phthalocyanine Chloride Tetrasulfonic acid (AlPcS4) [80] were 
produced. Two AlPcS4-liposome formulations were prepared; sonosensitive DOPE-based 
liposomes (DOPE:DSPC:DSPE-PEG 2000:Cholesterol 25:27:8:40 mol %) and non-
sonosensitive hydrogenated-soy-phosphatidylcholine (HSPC)-based liposomes (HSPC:DSPE-
PEG 2000:Cholesterol 57:5:38 mol %), the latter having the same membrane composition as 
Caelyx® [81]. 
10 μl liposome dispersion was injected directly into 22Rv1 prostate tumour xenografts 
implanted on the leg of nude mice. Fluorescent images were acquired pre and post tumour 
exposure to 1.13 MHz US for 1 min using a confocal US setup developed at INSERM, Lyon, 
France.
Figure 8 and 9 presents representative images of animals administered HSPC-based 
liposomes and DOPE-based liposomes, respectively. Tumour signal intensity was quantified 
by drawing a ROI around the tumour. The group receiving DOPE-based liposomes combined 
with US experienced a significant increase in signal intensity (110%, p<0.05). The group 
receiving HSPC-based liposomes and US did not experience a significant increase. Neither 
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did control animals, i.e. animals receiving no US between the two image acquisitions. The 
mean group relative increases in fluorescence signal for the different experimental groups are 
presented in Figure 10. 
Figure 8. Mouse administered intratumoral injection of AlPcS4-containing HSPC-based 
liposomes pre (A) and post (B) US treatment. The left animal is untreated control. 
Figure 9. Mouse administered intratumoral injection of AlPcS4-containing DOPE-based 
liposomes pre (A) and post (B) US treatment. The left animal is untreated control. 
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Figure 10. Mean group relative increase in fluorescence intensity. Group size and standard 
deviations are given. 
It should be added that iv administration of AlPcS4-containing DOPE-based liposomes with 
concurrent US treatment 5 or 24 hours later did not result in an increase in fluorescence 
intensity. This may be due to leakage in circulation, low tumour uptake, low assay sensitivity 
at lower concentrations or other reasons. It should also be emphasized that the current study 
included only a small number of animals. Firm conclusions may therefore not be made 
regarding in vivo sonosensitivity of current formulations. Nevertheless, the study provide 
support that US may induce drug release from liposomes in vivo.
5.2 Therapy study with DOPE-based liposomes 
Sonosensitive DXR containing DOPE-based liposomes (DOPE:DSPC:DSPE-PEG 
2000:Cholesterol 25:27:8:40 mol %), having identical membrane composition as DOPE-
based liposomes described in section 5.1 were administered as a single iv injection to mice 
bearing LEW2AX liposarcoma xenografts. The LEW2AX xenograft model was used since it 
grows more homogenously than the prostate xenografts used elsewhere in this thesis. A 
relatively high drug dosage of 14 mg DXR/kg was administered iv and US treatment was 
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performed 24 hours later by a focused 250 kHz setup for a duration of five minutes. US 
treatment alone did not produce any tumour growth inhibition in animals receiving saline. 
Neither did US enhance tumour growth inhibition in animals administered DOPE-based 
liposomal DXR (Figure 11). 
Figure 11. Tumour growth in mice. Group mean and standard deviations are given (n = 7 - 8). 
Paper II demonstrated that the current DOPE-based liposomes administered were highly 
sonosensitive in vitro as well as exhibiting prolonged circulation time, i.e. 17 % of 
administered drug were present in the blood 24 hours post injection. Consequently, it could 
presumably be anticipated that US would enhance the therapeutic effect of DOPE-based 
liposomal DXR. However, US did not have any enhancing effect. Numerous reasons may 
explain the absence of such effect including low US-sensitivity of liposomes in vivo, failure of 
US setup to deliver sufficient intensity in vivo or other reasons. However, the relatively high 
dose of liposomal DXR alone literary ceased tumour growth reaching therapy saturation 
levels. In retrospect, if US produced any additional effect it is unlikely that it could have been 
identified. Consequently, the study might illustrate that when assessing therapeutic response 
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in dual therapy modalities, administering excessive amounts of one agent renders it difficult 
to observed combined effects. 
36
6. Discussion 
The ability of liposomes to transport therapeutic agents to tumour tissue may render 
liposomes an interesting drug delivery strategy for combining with other treatment modalities. 
By modulating the liposomal membrane composition, liposomes can be given special features 
like sonosensitivity. DXR have been used for treating several cancers and is also well suited 
for encapsulation into liposomes. Further, as DXR is a potent radiosensitizer liposomal DXR 
may be feasible to combine with RT. 
In this thesis preclinical evaluations of dual therapy combining liposomal DXR with US and 
RT have been assessed in immunocompromised mice bearing human tumour xenografts. 
Subcutaneous tumour xenografts differ in many aspects from clinical tumours, e.g. they grow 
in anatomically inappropriate sites, rarely metastasize and grow very rapidly following 
implantation. The ability of tumour xenografts to predict clinical efficacy is therefore 
somewhat disputed. However, all therapeutic agents used for treating cancers clinically have 
also demonstrated activity in preclinical models [82]. 
6.1 Preclinical evaluation of sonosensitive liposomes 
Tumour accumulation of liposomes is a slow process requiring prolonged circulation time to 
enable sufficient uptake in tumour tissue [24]. Consequently, liposome research has for the 
last decades focused on developing liposomes that minimize MPS recognition in addition to 
being stable in the blood stream so that any pre-emptive drug leakage prior to tumour 
extravasation is reduced. However, upon tumour accumulation encapsulated drug has to 
become bioavailable prior to exerting cytotoxic actions [31]. Liposomal drug release for 
stable, long circulating liposomes like Caelyx® is a long process and several mechanisms 
responsible for drug release have been suggested; including slightly acidic pH found in 
tumours, lipases from dying tumour cells and metabolization of liposomes by tumour 
macrophages with concurrent release of free drug [24]. Caelyx® was not approved because of 
increased therapeutic effect over free DXR, but due to reduced cardiac toxicities [32]. The 
high stability is assumed to explain the absence of improved therapeutic outcome [32]. 
Finding methods to destabilize liposomes within tumour tissue may therefore lead to 
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substantial increase in drug bioavailability with concurrent improved therapeutic outcome 
[24]. Several strategies have been suggested for this purpose, including rendering liposomes 
US-responsive [83-85]. 
The presence of air has for long been considered necessary to produce drug release from 
liposomes and different strategies have been suggested including air containing liposomes 
[48,49] and liposomes linked to microbubbles [50,51]. However, the large size of such 
structures hinders extravasation in tumours limiting their use in cancer therapies. A growing 
line of evidence suggests that small liposomes (~100 nm) can be made US-sensitive by 
manipulating membrane compositions [52,53,83-85] enabling both proper extravasation and 
sonosensitivity. However, US-sensitivity and high stability in blood circulation have to be 
counterbalanced.
The liposomal membranes of stable, long circulating liposomes like Caelyx® usually have 
phospatidylcholine (PC) phospholipids as a major component. Such liposomes do not respond 
well to US treatment as indicated in Paper II and section 5.1. However, by including the 
phosphatidylethanolamine (PE) phospholipid DSPE as a major fraction in the liposome 
membrane, liposomes can be made US-responsive (Paper I). Also, DSPE-based liposomes 
(Paper I) appeared to remain stable in the blood circulation as acceptable kinetic profiles were 
demonstrated, i.e. ~10 % of administered DXR dose was present in the blood 24 hours post 
injection. Such kinetic studies provide information of total DXR content in the blood and do 
not give direct information regarding liposome stability. However, liposome integrity is 
considered necessary to achieve prolonged circulation times of DXR [24] and therefore the 
presence of substantial DXR levels in blood 24 hours post injection indicate high stability. 
Paper I also indicated that LFUS can increase the therapeutic effect of DSPE-based liposomal 
DXR when applied to prostate tumour xenografts 24 hours post injection. In vitro studies 
showed that LFUS induced ~20 % drug release after four minutes US treatment, presumably 
by destabilizing the liposomal membrane [83-85]. However, assuming that similar 
mechanisms could explain the enhanced therapeutic outcome is not unproblematic. Levels of 
dissolved gases, viscosity, purity, etc would be different in tumour tissue and it has to be 
expected that it would affect drug release. Further, liposome sonosensitivity may also be 
influenced by interaction with plasma proteins, cells, etc within tumour tissue. The observed 
tumour growth inhibition may therefore also result from other effects induced by US such as 
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heat production with increased extravasation of circulating liposomes [47], increased drug 
distribution in tumour tissue and increased drug uptake by cancer cells [37]. 
Paper II demonstrated that DOPE, a PE phospholipid traditionally used in pH-sensitive 
liposomes [86,87], is also suitable for rendering liposomes US-sensitive. While six minutes 
US treatment of DSPE-based liposomes yielded approx 25 % drug release (Paper I), identical 
US exposure of DOPE-based liposomes resulted in approx 90 % drug release indicating that 
DOPE is an even more potent modulator of sonosensitivity than DSPE. Importantly, kinetic 
studies demonstrated similar circulation times for liposomes comprising 25 and 32 mol % 
DOPE as for Caelyx® (Paper II) suggesting high stability within the blood circulation. In vivo
liposome sonosensitivity evaluation (section 5.1) suggested that DOPE-based liposomes also 
expressed high US sensitivity in vivo. It has to be emphasised that this was a small study and 
robust conclusions should not be made. However, the inclusion of PE phospholipids, 
especially DOPE, appears to be a promising strategy for manufacturing sonosensitive 
liposomes that remains stable in the blood circulation as indicated by prolonged circulation 
times of DXR. 
During preclinical therapy studies with animals bearing tumour xenografts the tumour is 
superficially located and easy accessed by non-focused LFUS treatment. Hence, LFUS has 
been used in several preclinical studies to combine with liposomal cytostatics [38,88,89]. In
vitro studies have suggested that LFUS may be more efficient than HFUS for inducing 
liposomal drug release, presumably because US intensities needed to induce transient 
cavitation is lower at lower US frequencies [46]. Clinical implementation may, however, 
require non-destructive focused US of higher frequencies to enable focused deposition of 
acoustic energy [90,91]. Still, trends in liposome sonosensitivity have been demonstrated to 
be similar irrespective of US assessments have been performed with LFUS or HFUS [84,85]. 
Treatment of PCa is at present, among other treatment options, routinely performed by radical 
prostatectomy, a procedure associated with significant side effects [12]. Combining 
sonosensitive liposomal cytostatics with US has the potential to provide a non-invasive 
alternative for treating clinically localized PCa. Moreover, other localized cancers may 
perhaps also be treated using the technology. 
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6.2 Optical imaging in the development of liposomal formulations 
Drug development is a long, high-risk and costly process. Out of 10.000 compounds 
evaluated in preclinical studies, five enter clinical trials and one receives US Food and Drug 
Administration (FDA) approval. The mean time from synthesis of a new compound to FDA 
approval is 14.2 years. For a review see [92]. Advances in imaging technologies have the 
potential to considerably accelerate this process [93]. During preclinical research medical 
imaging technologies allow biological processes to be studied in vivo in the same animal over 
a longer time interval. Such studies may reduce the number of animals needed and could 
potentially replace time consuming end-point analysis. 
During development of new liposomal formulations assessment of tumour drug uptake is and 
important but time consuming process. Performing such studies with OI would enable several 
product candidates to be evaluated faster with less demand on animals. The biodistribution of 
several drug carriers have been assessed using this technology [94-101]. Such studies would 
in most situations require labelling with a NIR fluorochrome. 
Due to the semitransparent nature of mammalian tissue light of a certain wavelength can 
excite exogenous applied fluorochromes within the body of small experimental animals. Upon 
excitation, light of a longer wavelength is emitted and can be detected on the body surface, 
i.e. reflectance fluorescence imaging, generating a surface map of fluorescence distribution 
[102].
From a practical point of view OI is cheaper, faster and easier to operate than most other 
imaging technologies [93,103]. Also, there is no need for radioactive agents and several 
animals may be imaged simultaneously generating data rapidly. However, light that passes 
through a medium is subjected to absorption and scattering and OI may therefore only be used 
for imaging depths up to one cm [102]. As tissue absorption is lowest at higher wavelengths, 
NIR fluorochromes are best suited for in vivo applications [102]. OI has been used for a 
variety of purposes in medical research as reviewed elsewhere [102]. 
In Paper III the feasibility of using OI to study liposome accumulation in tumours were 
evaluated. DiD-labelled PL-DXR were administered to tumour-bearing mice and tumour DiD 
and DXR levels determined ex vivo at 24 and 48 hours post injection. Analysis revealed 
40
higher levels of DXR than DiD in the blood at both 24 and 48 hours indicating dissociation of 
DiD from liposomes in the blood circulation. In vivo fluorescence acquisitions will under such 
circumstances not only image labelled liposomes but also dissociated dye. Moreover, only a 
weak association was observed between in vivo DiD tumour fluorescence intensity and actual 
tumour DiD levels (R2=0.59). The absence of a strong correlation was presumably due to 
absorption and scattering of in vivo DiD tumour fluorescence [102,104]. However, during 
image analysis the ROI is drawn manually along the edges of the tumour and poorly visible 
tumour margins may impede drawing of ROI. Also, fluorescence emitted from outside ROI 
may also preclude measurements. Consequently, several factors may have in combination 
reduced the sensitivity of the assay. 
Even if quantifying liposomal tumour uptake in absolute numbers may not be possible with 
OI, relative differences in tumour uptake between different liposomal formulations could 
perhaps be successfully evaluated on condition that there is no dissociation of the labelling 
fluorochrome within the blood circulation and that tumours are reasonably homogenous in 
size and shape. 
During development of drug containing sonosensitive liposomes sufficient drug release at 
target site should be evaluated. Extent of in vitro drug release from liposomes can be 
determined as described in Paper I and II. The extent of drug release in vivo is somewhat 
more complicated to evaluate. However, OI might be a promising method for this purpose as 
indicated in Section 5.1. 
6.3 Liposomal doxorubicin in combined chemoradioterapy 
During tumour growth impaired blood supply fail to deliver sufficient amounts of oxygen to 
growing tumours resulting in various degrees of hypoxia [55,56]. Hypoxia reduces the effect 
of RT and several strategies have been suggested to improve RT under hypoxic conditions 
[60,61].
Combining cytostatics with RT is used in the treatment of cancers to achieve increased 
efficacy [62,105]. DXR is a potent radiosensitizer and enhance the effect of RT presumably 
by inhibiting repair mechanisms following radiation induced DNA damage [64,65,106]. It has 
also been suggested that DXR reoxygenate tumours by reducing oxygen consumption in 
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tumour cells [107,108] rendering the tumour more sensitive to RT. Clinical studies have 
reported promising results by combining RT with conventional DXR in the treatment of 
various sarcomas [109-113]. However, as tumour tissue favours accumulation of liposomes, 
using PL-DXR in CRT may enhance efficacy primarily in tumour tissue [66]. 
Preclinical CRT studies, involving both PL-DXR [66,68] and non-pegylated liposomal DXR 
[69], have described enhanced therapeutic effects when combined with RT. Combining PL-
DXR with RT in clinical studies have also been performed. However, due to low number of 
patients and the simultaneous inclusion of other therapeutic agents in addition to PL-DXR and 
RT, assessing the beneficial effect of PL-DXR in some of these studies is somewhat difficult. 
Nevertheless, promising results are described for several cancers including breast cancer 
[114,115], sarcomas [67], non-small cell lung cancer [70,116,117], head and neck cancer [70], 
glioblastoma and metastatic brain tumours [118]. Also, less promising results are reported for 
non-small cell lung cancer [119] and glioblastoma [120]. However, according to my 
knowledge there has not been performed any major randomized trials with CRT involving 
PL-DXR.
Even though conventional DXR is reported to enhance the effect of RT, it is also reported to 
reduce tumour blood flow [121,122], presumably by inducing endothelial damage with 
concurrent vascular dysfunction [123-125]. In contrast, PL-DXR is reported to normalize 
tumour blood flow [126] indicating that PL-DXR may be beneficial in CRT not only by 
increasing the effect of RT primarily in tumour tissue but also by reducing DXR mediated 
adverse effects on tumour vascular functions. As suggested in Paper IV, PL-DXR produced 
therapeutic effect without significantly altering tumour vascular functions as judged by DCE 
MRI and immunohistochemistry. For co-administration with RT this is beneficial because 
well vascularised tumours may have less degree of hypoxia. The presence of oxygen in 
tumours is vital due to 1) the production of radicals and thus DNA damage and 2) to prevent 
DNA repair by fixating the damage [127]. DXR may therefore resemble oxygen in tumours 
exposed to RT. It has to be emphasised that this study was performed using a drug dose of 3.5 
mg DXR/kg and the result may not be valid for other drug doses. Other drug doses may, 
perhaps, produce vascular alterations limiting tumour blood flow. 
Hypoxia is a common feature of most tumours [127] and the ability to achieve effective RT 
under hypoxic conditions is therefore of great importance. Paper IV demonstrated that the 
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effect of RT is greatly reduced by hypoxia. Here, hypoxia was induced by clamping the 
tumour-bearing leg creating ischemia with concurrent hypoxia. It has to be anticipated that 
temporary episodes of acute hypoxia induced this way would differ from hypoxia in clinical 
tumours. However, the concomitant administration of PL-DXR improved therapeutic 
outcome indicating that PL-DXR may increase the effect of RT under hypoxic conditions. 
Overcoming hypoxia by administering radiosensitizing drugs may be of limited value as 
supply to hypoxic regions are commonly reduced by inadequate vascularisation. However, 
PL-DXR seems to have a positive effect on vascular functions as suggested in paper IV. Here, 
vascular alterations induced by hypoxic RT were apparently reduced by co-administration of 
PL-DXR as judged by DCE MRI. 
Data analysis of DCE MRI was performed by identifying three kinetic parameters A, Kep and 
Kel (Paper IV). However, the Kep parameter, which identifies the transfer rate between plasma 
and EES, had to be excluded from the study as non-physiological values were generated both 
pre and post treatment. Rapid contrast agent in-wash originating from high permeability 
and/or high perfusion could provide an explanation. Moreover, methodological limitations 
may also be suggested. I.e. registering contrast transfer between plasma and EES is influenced 
by the speed of contrast administration [75]. Also, limitations in time resolution could further 
explain why the kinetic model did not generate meaningful Kep values. Due to unsuccessful 
contrast administration or tumour sizes being too small to enable reliable DCE MRI analysis 
it was not possible to generate A and Kel values for all animals that entered the study. 
DXR exert cytotoxic effects by interfering with several cellular processes [128] and numerous 
mechanisms may explain the radiosensitizing properties of DXR. However, as all tumours 
have some degrees of hypoxia [129], the ability of PL-DXR to increase the effect of RT under 
hypoxic conditions could provide some explanation to why PL-DXR increase the effect of 
RT. For drugs that affect tumour vascular functions liposomes may be an interesting drug 
delivery technology for use in CRT. 
To my knowledge there have been no clinical studies on CRT involving PL-DXR on PCa. 
Even though results obtained from preclinical studies frequently fail in predicting clinical 
results [82], the ability of PL-DXR to increase the effect of RT under hypoxic conditions in 
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xenograft models are nontrivial as it is well documented that hypoxia reduces the effect of RT 
in PCa [57-59]. 
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6. Conclusions 
The work presented in this thesis suggests that PL-DXR can produce enhanced effects when 
combined with other treatment modalities, i.e. US and RT, as judged by assessment in 
preclinical models. Further, OI appears not to be promising for performing biodistribution 
studies of fluorescence labelled liposomes. The following conclusions can be made: 
• Including DSPE as a major fraction in the liposomal membrane can render liposomes 
US-sensitive with acceptable circulation time. 
• LFUS can enhance the therapeutic effect of DSPE-based liposomal DXR in mice 
bearing prostate cancer xenografts. However, the benefit of LFUS treatment appears to be 
modest but statistically significant. 
• DOPE appears to be a potent modulator for sonosensitivity. However, high DOPE 
content reduces liposome stability in the blood stream. 
• Dissociation of DiD from liposomes in the blood stream limits the suitability of DiD 
as a marker for liposomes in vivo.
• Scattering and absorption of light limits the usefulness of OI for assessing the 
biodistribution profile of fluorescence labelled liposomes. 
• PL-DXR induces antitumour effect apparently without influencing tumour vascular 
functions at a dose of 3.5 mg DXR/kg. Further, PL-DXR appears to reduce some of the 
vascular alterations induced in hypoxic tumours by RT.  
• PL-DXR increases the therapeutic effect of RT in radioresistant tumour xenografts. 
45
7. Perspectives 
This thesis has demonstrated that antitumour effect of sonosensitive liposomal DXR in animal 
models can be enhanced by concurrent LFUS treatment. However, further manipulation of 
liposome membrane composition may generate sonosensitive liposomes with properties 
superior to those described in this thesis. Also, focused US of higher frequencies may be used 
to restrict acoustic cavitation to tumour tissue. Therapeutic assessment of DOPE-based 
liposomal DXR and US of higher frequencies (500 kHz - 1.13 MHz) will be tested in mice 
bearing prostate and breast cancer xenografts in near future. 
Studying liposomal biodistribution by OI demands strong bonding between liposome and 
labelling fluorochrome. As DiD appears to dissociate in vivo, finding stable labelling 
techniques may improve quality of assay. However, it has to be anticipated that liposomes at 
some time post injection will disintegrate. In such case the labelling fluorochrome will no 
longer label intact liposomes. Consequently, it has to be questioned whether OI is a suitable 
technique for studying the biodistribution profile of labelled liposomes. 
Several reports have demonstrated that PL-DXR increases the effect of RT, also under 
hypoxic condition as suggested in this thesis. However, using other drug doses or different 
time intervals between drug administration and start of RT may improve therapeutic outcome. 
As the biodistribution profiles of drugs are changed by liposomal encapsulation, 
encapsulating other radiosensitizing drugs may perhaps be an interesting drug delivery 
strategy.
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Abstract 
Background: Tumor vasculature frequently fails to supply sufficient levels of oxygen to 
tumor tissue resulting in radioresistant hypoxic tumors. To improve therapeutic outcome 
radiotherapy (RT) may be combined with cytotoxic agents.  
 
Methods: In this study we have investigated the combination of RT with the cytotoxic agent 
doxorubicin (DXR) encapsulated in pegylated liposomes (PL-DXR). The PL-DXR 
formulation Caelyx® was administered to mice bearing prostate carcinoma xenografts, in 
combination with RT performed under normoxic and hypoxic conditions. Treatment response 
evaluation consisted of tumor volume measurements and dynamic contrast-enhanced 
magnetic resonance imaging (DCE MRI) with subsequent pharmacokinetic analysis using the 
Brix model. Imaging was performed pre-treatment (baseline) and 8 days later. Further, 
hypoxic fractions were determined by pimonidazole immunohistochemistry of excised tumor 
tissue.  
 
Results: As expected, the therapeutic effect of RT was significantly less effective under 
hypoxic than normoxic conditions. However, concomitant administration of PL-DXR 
significantly improved the therapeutic outcome following RT in hypoxic tumors. Further, the 
pharmacokinetic DCE MRI parameters and hypoxic fractions suggest PL-DXR to induce 
growth-inhibitory effects without interfering with tumor vascular functions.  
 
Conclusions: We found that DXR encapsulated in liposomes improved the therapeutic effect 
of RT under hypoxic conditions without affecting vascular functions. Thus, we propose that 
for cytotoxic agents affecting tumor vascular functions liposomes may be a promising drug 
delivery technology for use in chemoradiotherapy.  
 2 
Background 
During tumor growth abnormal tumor vasculature frequently fails to supply sufficient levels 
of oxygen to tumor tissue, resulting in various degrees of hypoxia [1,2]. Tumor hypoxia is 
known to cause treatment resistance and to promote metastatic disease progression [3-5]. To 
improve radiotherapy (RT) efficacy of radioresistant tumors, several approaches have been 
suggested [6,7]. One strategy is to combine conventional cytotoxic agents with RT to increase 
the therapeutic effects, i.e. chemoradiotherapy (CRT) [8,9]. 
 
The anthracycline chemotherapeutic drug doxorubicin (DXR) has been demonstrated to 
enhance the therapeutic effect of RT [10-13], presumably by preventing cells from repairing 
radiation-induced DNA damage [11-13]. DXR has also reportedly enhanced the effect of RT 
under experimental in vitro hypoxic conditions [14]. 
 
By encapsulating DXR in liposomes, DXR accumulation in the heart is reduced, resulting in 
less cardiac toxicities compared to conventional DXR [15,16]. Abnormal tumor vasculature 
also favors accumulation of liposomes due to the enhanced permeability retention effect [17]. 
Moreover, by incorporating polyethylene glycol (PEG) in the liposomal membrane, clearance 
by the cells of the reticulo-endothelial system is reduced, resulting in prolonged circulation 
time [18]. 
 
Liposomes accumulated in the tumor may act as depots for sustainable drug release, making 
them particularly beneficial during a course of CRT, since daily drug dosing would be 
needless [19]. Also, as liposomes avoid accumulation in healthy tissue, radiation enhancement 
may primarily be located to tumors, reducing toxicities in neighboring healthy tissues [19,20]. 
Pegylated liposomal DXR (PL-DXR) has been shown to increase the effect of RT in 
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preclinical studies [19,21] and promising results are also achieved in clinical applications 
[20,22]. 
 
The objective of this study was to evaluate the potential therapeutic benefit of administering 
PL-DXR (Caelyx®) to tumor-bearing mice receiving RT under hypoxic, radioresistant 
conditions. Therapy-mediated changes in tumor vascular functions and tumor hypoxia were 
assessed by dynamic contrast-enhanced magnetic resonance imaging (DCE MRI) and 
pimonidazole immunohistochemistry, respectively. 
 4 
Methods 
Materials
The PL-DXR product Caelyx® was supplied by the pharmacy at the Norwegian Radium 
Hospital, Oslo, Norway (European distributor; Schering-Plough). Pimonidazole hydrochloride 
was supplied by Natural Pharmacia International, Inc., Burlington, MA, USA, and the 
contrast agent Dotarem® was from Laboratoire Guerbet, Paris, France. Dako EnVision™+ 
System-HRP (DAB) was supplied by Dako Corporation, DA, USA. 
 
For anaesthesia of mice a mixture of 2.4 mg/ml tiletamine and 2.4 mg/ml zolazepam (Zoletil® 
vet, Virbac Laboratories, Carros, France), 3.8 mg/ml xylazine (Narcoxyl® vet, Roche, Basel, 
Switzerland) and 0.1 mg/ml butorphanol (Torbugesic®, Fort Dodge Laboratories, Fort Dodge, 
IA, USA) was prepared and used. 
 
Experimental animals 
Male athymic nude Balb/c mice were provided by the Department of Comparative Medicine 
(animal facility), Oslo University Hospital. The CWR22 xenograft model, originating from a 
human, primary prostate carcinoma [23], was serially transplanted between mice. In brief, by 
blunt dissection through a skin incision tumor fragments (~2x2x2) mm3 were subcutaneously 
implanted on the upper leg (proximal to the knee joint) of 4 - 5 weeks old mice. The skin 
incision was sealed with topical skin adhesive. Approximately three weeks later a tumor 
xenograft of 5 - 10 mm in diameter developed. The mice were housed in transparent boxes 
with bedding material, fed ad libitum and kept under specific pathogen-free conditions. The 
temperature and relative humidity were kept constant at 20 - 21°C and 60 %, respectively. At 
the end of the experiments all animals were euthanized by cervical dislocation. All procedures 
were performed according to protocols approved by the National Animal Research Authority 
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and carried out in compliance with the European Convention for the Protection of Vertebrates 
Used for Scientific Purposes.  
 
Radiotherapy
RT was delivered at a dose of 2 Gy/day for five consecutive days (at experiment days 1 – 5) 
using a 60Co source (Mobaltron 80, TEM instruments, Crawley, UK) with a dose rate of 0.8 
Gy/min. The animals were located in a custom designed vicryl tube with an opening for the 
tumor bearing leg to be stretched out and fixated horizontally. During the procedure only the 
tumor bearing leg was extended into the radiation field, limiting radiation exposure to the 
remaining body. The procedure was performed under sedation induced by 0.05 ml of 
anesthetic agent. 
 
Hypoxic radiotherapy 
Tumor hypoxia was experimentally induced by placing the animals in a vicryl tube. A rubber 
band was clamped around the leg of the animal, proximal to the xenograft. The rubber band 
was left on for five minutes prior to and during RT (at experiment days 1 – 5). During 
clamping the animal’s leg temporary turned bluish, indicating stagnation of blood circulation 
with concurrent induction of acute hypoxia. The discoloration disappeared rapidly following 
removal of the rubber band and no animals became lame or experienced any adverse effects 
from the clamping. The procedure was performed under sedation induced by 0.05 ml of 
anesthetic agent. 
 
PL-DXR
PL-DXR was administered at a dose of 3.5 mg DXR/kg as a single i.v. bolus injection 
through the tail vein (at experiment day 0). The rationale for using the relatively low drug 
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dose was to avoid reaching therapy saturation levels where any additional effect produced by 
hypoxic RT would not be detected. 
Monitoring of treatment response 
Animals bearing tumor xenografts sized 5 - 10 mm in diameter were randomly allocated into 
different experimental groups of 8 - 10 tumors each (Table 1). At the start of the experiment 
all animals were imaged by DCE MRI with subsequent i.v. administration of PL-DXR to 
animals designated to the PL-DXR groups. RT treatment began 24 hrs later, enabling 
sufficient time for liposomal tumor accumulation. During daily RT sessions all animals, 
regardless of experimental group, were sedated. To assess therapy-induced changes in tumor 
vascular function all animals were subjected to an identical imaging protocol 8 days after the 
pre-treatment DCE MRI. 
 
Tumor volumes were estimated after measuring the tumors' shortest and longest diameters 
with four days intervals using a digital caliper (Model B220S, Kroeplin, Schlüchtern, 
Germany). The tumor volume was calculated according to the formula (/6)*length2*width 
[24]. 
 
DCE MRI acquisitions 
MRI acquisitions were performed as previously described [25], using a 1.5 T GE Signa LS 
scanner (GE Medical Systems, Milwaukee, WI), and a dedicated MRI mouse coil [26]. Prior 
to MRI, a heparinized 24 G catheter attached to a cannula containing 0.01 ml/g body weight 
contrast agent (Dotarem®, diluted in heparinized saline to 0.06 M) was inserted into the 
animals’ tail vein. The animals were placed in an adapted cradle and put into the coil, before 
being placed in the scanner. During image acquisition, the animal’s temperature was 
maintained at 38 °C. First, the tumor was localized using axial fast spin-echo (FSE) T2-
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weighted (T2W) images (echo time (TEeff) = 85 ms, repetition time (TR) = 4000 ms, echo 
train length (ETL) = 16, image matrix (IM) = 256 × 256, field-of-view (FOV) = 4 cm, slice 
thickness (ST) = 2 mm). Second, DCE MRI was obtained with a dynamic fast spoiled 
gradient-recalled (FSPGR) T1W sequence (TE = 3.5 ms, TR = 180 ms, IM = 256 × 128, FOV 
= 6 cm, ST = 2 mm, and flip angle (FA) = 80°). Following 5 baseline T1W image 
acquisitions, contrast kinetics were investigated by injecting the contrast agent during 3 
seconds and performing 20 minutes of post-contrast imaging. The time resolution was 12 
seconds and the reconstructed voxel size was 0.23 × 0.23× 2 mm3. 
DCE MRI analysis 
Image analysis was performed using in-house developed software in IDL (Interactive Data 
Language v 6.2, Research Systems Inc., Boulder, CO). For the central slice of each tumor, a 
region of interest (ROI) was manually traced in T1W images, excluding surrounding skin and 
connective tissue. The time-dependent relative signal intensity, RSI(t), was calculated for each 
image voxel according to Equation 1. 
 
Equation 1:  
SI(0)
 SI(0)- SI(t)
RSI(t) =  
 
where SI(0) refers to the pre-contrast signal intensity and SI(t) the post-contrast signal 
intensity in the voxel at time t. Pharmacokinetic modeling was performed using the Brix 
model [27], with the RSI(t) for each voxel as input. The Brix model is a two-compartment 
pharmacokinetic model where the contrast agent is assumed to distribute between two 
individually well-mixed compartments; the blood plasma and the extracellular extravascular 
space (EES) in the tumor. The i.v. injected contrast agent is transported into the tumor by 
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perfusion, where it diffuses between the plasma and the EES, before being eliminated at a 
constant rate.
 
Using the RSI(t) for each voxel in the tumor ROI, the Brix model (equation 2) was fitted using 
the Levenberg-Marquardt least-squares minimization method (MPFIT; 
http://purl.com/net/mpfit) [28]. 
 
Equation 2:  )
telk-e-
tep-ke(
kk
Ak
RSI(t)
epel
ep  
 
where the parameter kep is the rate constant between plasma and EES, kel the clearance rate of 
contrast agent from plasma, and A an amplitude parameter related to the size of the EES. 
 
Immunohistochemistry of tumor hypoxia 
In addition to the animals subjected to DCE MRI, parallel groups of animals were followed to 
harvest tumor tissue at the same time-point as the day 8 MRI acquisitions. Animals designated 
to immunohistochemistry examination received identical treatments as animals used for tumor 
growth assessment and DCE MRI (Table 1), with each group containing 8 tumors. Hypoxia 
was determined by injecting 80 mg/kg pimonidazole hydrochloride (1-[(2-hydroxy-3-
piperidinyl)propyl]-2-nitroimidazole hydrochloride, dissolved in saline i.p. One hour later 
euthanasia was performed by cervical dislocation and tumors were excised and preserved in 
phosphate-buffered 4 % formalin until tissue sectioning. Tumor hypoxia was detected using a 
peroxidase-based immunostaining method. In brief, tissue sections were stained using the 
Dako EnVision™+ System-HRP (DAB) (K4011) and Dakoautostainer. Deparaffinization and 
unmasking of epitopes were performed using PT-Link (DAKO) and EnVision™ Flex target 
retrieval solution, high pH. To block endogenous peroxidase, sections were treated with 0.03 
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% hydrogen peroxide for 5 minutes. The preparations were incubated 30 minutes with 
polyclonal rabbit antibodies to pimonidazole-protein adducts (1:10000 dilution). The sections 
were then incubated with peroxidase-labeled polymer conjugated to goat anti-rabbit 
secondary antibodies for 30 minutes. The tissue sections were stained for 10 minutes with 
3’3-diaminobenzidine tetrachloride (DAB) and counterstained with haematoxylin, dehydrated 
and mounted in Diatex. 
 
Statistical analysis 
By means of a multiple regression procedure differences in tumor growth between the 
experimental groups were operationally represented by three between group comparisons; 1) 
comparing the RT group with the hypoxic RT group, 2) comparing the RT group with the PL-
DXR group and finally, 3) comparing the hypoxic RT group with the PL-DXR + hypoxic RT 
group. Tumor growth was represented by linear and quadratic developmental trends. 
Group differences in DCE MRI parameters and hypoxic fractions were analyzed by 
student’s t-tests, and the Pearson correlation (r) test analyzed whether correlations between 
variables were significant using SPSS 16.0 (SPSS, Cary, NC). A significance level of 5 % 
was used for all statistical analyses.
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Results 
Tumor growth 
Tumor volume measurements were performed with four days intervals for 29 days, except for 
the control group where animals were euthanized at day 21 when the tumor diameters 
exceeded 20 mm, i.e. in accordance with internal regulations for animal experiments. Based 
on the 21 days observation period, the tumor growth of the control group was significantly 
enhanced as compared to all the groups receiving treatment (p<0.050). The differences in 
tumor growth between the remaining groups were analyzed on the basis of the 29 days 
observation period. Based on quadratic developmental trends the hypoxic RT group showed 
significantly less therapeutic effect than the normoxic RT group (comparison 1, p=0.006). 
The group receiving PL-DXR also presented significantly less therapeutic effect than the RT 
group (comparison 2, p=0.008). Interestingly, tumor growth in the PL-DXR + hypoxic RT 
group was significantly reduced compared to the hypoxic RT group (comparison 3, p=0.004). 
Tumor growth patterns are portrayed in Figure 1. No adverse effects were observed in any of 
the experimental groups.  
 
Treatment monitoring using DCE MRI 
Following Brix modeling of contrast kinetics, parametric images of A, kel and kep were 
produced. The kep parameter is a parameter mainly related to the in-wash of contrast agent 
from plasma to extravascular space. Due to a very rapid contrast agent in-wash, presumably 
caused by high permeability and/or high perfusion, some tumor voxels were saturated, 
precluding estimation of reliable mean tumor values of kep for subsequent intergroup 
comparisons. The kep parameters were therefore excluded. Also, due to unsuccessful injection 
of contrast agent or technically related issues, some of the tumors in the experiment were 
excluded from subsequent pharmacokinetic analysis. Further, some of the tumors were too 
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small to enable reliable DCE MRI analysis. The exact number of tumors that underwent MRI 
and image analysis is indicated in all relevant figures onwards.  
 
In Figure 2, the mean group relative change in the A parameter from day 0 to day 8 is 
presented. A reduction in the A parameter was observed for both the control (18 %) and the 
PL-DXR (26 %, p=0.030) groups. All groups receiving radiation experienced a relative 
increase from day 0 to day 8, being 4 % in the PL-DXR + hypoxic RT group, 20 % (p=0.002) 
in the hypoxic RT group and 29 % (p=0.046) in the RT group. No significant intergroup 
difference in the A parameter was observed when comparing the control tumors with tumors 
treated with PL-DXR. However, all groups receiving radiation experienced a significant 
increase in the A parameter compared to the control group; PL-DXR + hypoxic RT (p=0.019), 
hypoxic RT (p=0.001) and RT (p=0.006). Additionally, the group receiving PL-DXR + 
hypoxic RT also experienced an increase in the A parameter compared to PL-DXR (p=0.026) 
and a decrease compared to hypoxic RT (p=0.025) and RT (p=0.049). 
 
In Figure 3, the mean group relative change in the kel parameter from day 0 to day 8 is 
presented. Three groups experienced an increase in kel, being 45 % in the control group, 85 % 
in the PL-DXR group and 47 % in the PL-DXR + hypoxic RT group. Due to large intragroup 
variations, these increases were not significant. Both the hypoxic and normoxic RT groups 
experienced a 27 % decrease in the kel parameter with the change in the hypoxic RT group 
being significant (p=0.007). No intergroup differences in the kel parameter were observed 
when comparing the control tumors with the tumors that received PL-DXR or PL-DXR + 
hypoxic RT. However, both the hypoxic RT group and the RT group experienced significant 
reductions in the kel parameter compared to the control group, (p=0.015 and p=0.020, 
respectively). 
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Immunohistochemistry of tumor hypoxia 
Parallel to tumor growth and DCE MRI studies identically treated groups of tumors were 
excised and used to assess tumor hypoxia at day 8, coinciding with the time-point of post-
treatment MRI acquisitions. Figure 4 presents the hypoxic fractions of the different 
experimental groups. The mean hypoxic fractions were 23 % for the control tumors, 21 % for 
tumors treated with PL-DXR alone, 14 % for the tumors receiving both PL-DXR and hypoxic 
RT, 15 % for tumors receiving hypoxic RT, and 11 % for tumors receiving RT. Compared to 
the control group, only the RT group presented significantly reduced hypoxic fractions 
(p=0.041).  
 
Correlations 
Figure 5 shows the correlations between the mean group hypoxic fractions at day 8 (%) versus 
the mean group relative change in the A parameter from day 0 to day 8 (%) (Figure 5A), the 
mean group relative change in the kel parameter from day 0 to day 8 (%) (Figure 5B), and the 
mean group relative change in tumor volumes from day 0 to day 9 (%) (Figure 5C), 
respectively. The mean group hypoxic fractions showed a strong negative correlation to the 
mean group relative change in the A parameter from day 0 to day 8 (r=-0.93, p=0.022), a 
weaker and insignificant positive correlation to the mean group relative change in the kel
parameter from day 0 to day 8 (r =0.74, p=0.155), and a positive correlation to the mean 
group tumor volume change from day 0 to day 9 (r=0.94, p=0.019).  
 
Figure 6 shows the correlations between the mean group relative change in tumor volumes 
from day 0 to day 9 (%) versus the mean group relative change in the A parameter from day 0 
to day 8 (%) (Figure 6A) and the mean group relative change in the kel parameter from day 0 
to day 8 (%) (Figure 6B), respectively. Mean group tumor volume change correlated 
negatively to the mean group relative change in the A parameter (r=-0.91, p=0.030) from day 
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0 to day 8, and positively, but not significantly, to the mean group relative change in the kel
parameter (r=0.75). 
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Discussion 
Tumor hypoxia prevent effective RT [3-5], and several strategies to improve RT efficacy 
under hypoxic conditions have been described [6,7]. The ability of PL-DXR to enhance the 
therapeutic effect of fractionated and single dose RT has previously been reported [19,21]. In 
the current study we demonstrated that PL-DXR improves the therapeutic effect of RT also 
under hypoxic conditions. Moreover, as it is important to develop strategies to monitor 
treatment responses non-invasively, DCE MRI appears to be promising for this purpose. 
 
The current PL-DXR formulation accumulates slowly in tumors, reaching peak levels 2-3 
days post injection in tumor xenograft models [29,30]. Consequently, substantial levels of PL-
DXR in the tumors during the five days of RT were expected. Any RT-mediated changes in 
tumor vascular functions that could interfere with tumor liposome accumulation was expected 
to be minimal as RT previously has reported to not alter liposomal tumor uptake [31,32]. 
 
Free DXR is reported to decrease tumor blood flow [33,34], subsequently reducing the 
oxygen levels in tumors. In contrary, PL-DXR has been suggested to normalize tumor 
vasculature [35]. In the current study there was no significant difference between the control 
and the PL-DXR group in any of the DCE MRI derived kinetic parameters or hypoxic 
fractions, suggesting that PL-DXR did not alter vascular functions. Still, tumor growth was 
significantly inhibited indicating that PL-DXR may exert tumoricidal effects without 
interfering with tumor blood circulation. This feature is highly beneficial with respect to 
subsequent RT since well oxygenated and vascularized tumors more likely respond better to 
RT.  
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In contrary, RT induced changes in the tumor vasculature both in the hypoxic and normoxic 
tumors, as measured by an increase in the A parameter. This alternation may be related to an 
increased interstitial volume, and a reduced elimination rate of contrast agent, as indicated by 
the kel parameter. The increase seen in the A parameter may be related to radiation-induced 
necrosis and/or edema, and thus increased interstitial volume. Further, an increase in the A 
parameter may reflect disrupted membranes increasing the extracellular volume due to 
elevated membrane permeability. Finally, the observed reductions in the kel parameter may 
reflect radiation-induced endothelial cell death, making clearance of contrast agent less 
effective. Interestingly, when hypoxic RT was administered in combination with PL-DXR 
these changes became less evident, indicating that PL-DXR reduced some of the vascular 
effects caused by RT in hypoxic tumors. 
 
Figure 5A shows that the hypoxic fractions were significantly correlated to the changes in the 
A parameter from day 0 to day 8. A similar relation has also been found in a clinical DCE 
MRI study of cervical cancer, where a positive correlation between the A parameter and 
oxygen levels, as measured by Eppendorf pO2 histography, was evidenced [36]. This may 
suggest the A parameter as a candidate biomarker of tumor hypoxia, for further investigation. 
The kel parameter correlated less to hypoxia, as seen in Figure 5B. Moreover, hypoxic 
fractions correlated significantly (Figure 5C) with tumor volume changes and may explain 
why the measured hypoxic fractions were highest in the control tumors and lowest in the 
tumors receiving the most effective treatments. Hypoxia and tumor size have also previously 
been demonstrated to correlate strongly [37]. 
 
The treatment-induced changes in the A parameter correlated significantly and negatively to 
tumor volume changes (Figure 6A), and changes in the kel parameter correlated strongly and 
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positively, although not significantly, to these volume changes (Figure 6B). This is promising 
with respect to developing DCE MRI and pharmacokinetic image analysis as tools for non-
invasive monitoring of therapeutic effects. 
 
The presence of oxygen in tumors exposed to RT is crucial because oxygen 1) enhance the 
yield of radiation-induced radicals and thus DNA damage, and 2) prevent repair of induced 
DNA damage by fixation of the damage [38]. DXR enhances the therapeutic effect of RT 
presumably by preventing cells from repairing radiation-induced DNA damage [11-13]. DXR 
may therefore resemble the effect of oxygen in tumors exposed to RT. Hypoxia is a common 
feature amongst most clinical tumors [39]. Overcoming hypoxia by administration of 
radiosensitizing drugs may nevertheless be of limited success as supply to hypoxic regions 
commonly are hampered by inadequate vascularization. Liposomal DXR seems however to 
have a positive effect on the tumor vascular functions as shown in this study. 
 
 
Conclusion
The present study shows that PL-DXR improves the therapeutic effect of RT under hypoxic 
conditions and that PL-DXR does not affect tumor vascular functions. Interestingly, PL-DXR 
appeared to reduce some of the vascular alterations induced in hypoxic tumors by RT. Hence, 
for drugs that affect tumor vascular functions liposomes may be a promising drug delivery 
technology for use in CRT.
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Figures 
Figure 1 – Tumor growth patterns for the experimental groups  
Presented as mean ± SEM (n = 8 – 10 per group). The control group was removed from the 
study at day 21 due to tumor diameters exceeding 20 mm. 
 
Figure 2 – Relative change in the A parameter (mean ± SEM) from day 0 to day 8 for the 
experimental groups 
3.5 mg/kg PL-DXR was administered after pre-treatment DCE MRI. RT was delivered at a 
dose of 2 Gy/day for 5 consecutive days, starting 24 hours after the pre-treatment DCE MRI. 
Hypoxia was induced by clamping the tumor-bearing leg 5 minutes prior to and during RT. 
Significant differences (p<0.050) to the control or PL-DXR + hypoxic RT groups are 
indicated with # or ×, respectively.
Figure 3 – Relative change in the kel parameter (mean ± SEM) from day 0 to day 8 for 
the experimental groups 
3.5 mg/kg PL-DXR was administered after pre-treatment DCE MRI. RT was delivered at a 
dose of 2 Gy/day for 5 consecutive days, starting 24 hours after pre-treatment DCE MRI. 
Hypoxia was induced by clamping the tumor-bearing leg 5 minutes prior to and during RT. 
Significant differences (p<0.050) to the control or PL-DXR + hypoxic RT groups are 
indicated with # or ×, respectively. 
Figure 4 – Hypoxic fractions in the experimental groups at day 8 assessed from 
pimonidazole immunohistochemistry of tumor tissue sections  
Group mean and SEM are shown, with n = 8 per group. 3.5 mg/kg PL-DXR was administered 
24 hours prior to RT. RT was delivered at a dose of 2 Gy/day for 5 consecutive days. Hypoxia 
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was induced by clamping the tumor-bearing leg 5 minutes prior to and during RT. A 
significant difference (p<0.05) to the control group is indicated with #.
Figure 5 – Hypoxic fractions versus DCE MRI parameters and tumor volumes 
Correlations between the mean group hypoxic fractions (%) at day 8 versus the mean group 
relative change in the A parameter from day 0 to day 8 (%) (A), the mean group relative 
change in the kel parameter from day 0 to day 8 (%) (B), and the relative change in mean 
group tumor volumes from day 0 to day 9 (%) (C), respectively.
 
Figure 6 – Tumor volume changes versus DCE MRI parameter changes 
Correlations between the mean group relative change in tumor volumes (%) from day 0 to day 
9 (%) versus the mean group relative change in the A parameter from day 0 to day 8 (%) (A), 
and the mean group relative change in the kel parameter from day 0 to day 8 (%) (B), 
respectively. 
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Table 1. Overview of treatments administered to the different experimental groups. 
Experimental groups Treatment
Control No treatment 
PL-DXR 3.5 mg DXR/kg (day 0) 
PL-DXR + hypoxic RT 3.5 mg DXR/kg (day 0) + clamping + 2 Gy/day for 5 days (day 1 – day 5) 
RT 2 Gy/day for 5 days (day 1 – day 5) 
Hypoxic RT Clamping + 2 Gy/day for 5 days (day 1 – day 5) 
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